UPCOMING LIVE WEBINAR

The R&D Tax Credit in the Natural Medicine Industry

Date and Time: There are no webinars running at this time

R&D Tax Credits: 80% of eligible companies do not claim them! Every year, companies waste thousands or even hundreds of thousands of dollars due to simple misunderstandings about the Research and Development (R&D) tax credit. Amendment claims can go back three years and in most cases generate substantial refunds for past R&D activities.

Date and Time: Thursday, October 2, 2030 at 1:00 PM CT | Duration: 60 Minutes

WEBINAR DETAILS

Title: The R&D Tax Credit in the Natural Medicine Industry

Date: There are no webinars running at this time

Time: There are no webinars running at this time

Cost: FREE

Learning objectives include:

An overview of R&D Tax Credits
Identifying Qualifying Research Activities
Defining the 4-Part Test
How to substantiate activities through documentation
Identifying Qualifying Research Expenses

Knowledge Level: Basic*
Date: Thursday, October 2, 2030
Time: 1:00 PM – 2:00 PM Central Time

Join the Webinar Here

Ask a Question Here

Click Here to Access the Attendance Form

Click Here to Contact the Technical Team

What we do?

Are You Elegible?

Pass an audit?

Our Difference

We care about price – Our fees are the most competitive in the market.
We care about risk – We are one of the most conservative, if not the most conservative, R&D tax credit providers in the market.
We are here to stay – We are one of the largest specialist R&D tax credit firms in America. We provide R&D tax credit services exclusively and take a long-term view.
We think we are the best – We do one thing, and we do it better than anyone else because it is the only thing we do.

Founded in 1984

Cybersecurity Accredited

Risk Management Accredited

iso 31000 risk management certification stamp vector

Framework Element	Description	Implication for Clients
Six-Eye Review	A mandatory internal review of every claim by a qualified engineer, a scientist, and a CPA (Certified Public Accountant) or Enrolled Agent.	Ensures the claim is technically valid, financially accurate, and compliant with tax law, maximizing its defensibility.
ISO 31000:2009 (Risk Management)	An international certification for the firm’s comprehensive risk management policies and processes.	Provides objective third-party validation of the firm’s commitment to mitigating tax risk for the client.
ISO 27001 (Information Security)	A global benchmark for establishing and maintaining an information security management system (ISMS).	Guarantees the highest level of protection for sensitive intellectual property and confidential financial data.

Schedule a Teleconference

Small businesses in the pharmaceutical sector can significantly benefit from the R&D Tax Credit, transforming their innovative efforts into substantial tax savings. This credit directly reduces federal tax liability, freeing up capital that can be reinvested in further research, development of new drugs, medical devices, or improved manufacturing processes. Crucially, eligible startups and pre-revenue companies can utilize the R&D payroll tax offset, which allows them to apply a portion of their R&D credit against the employer’s share of FICA social security taxes. This immediate cash benefit offsets personnel costs, providing vital liquidity for young companies that often operate at a loss while pursuing groundbreaking pharmaceutical advancements.

Deadline Calculator

Research Grants

Choose your industry

Pharmaceutical Case Study

Pharmaceutical companies are constantly working to develop innovative medicines and therapies that improve patient outcomes and address unmet medical needs. This process involves extensive research and development (R&D), including drug discovery, chemical synthesis, preclinical testing, and clinical trials. However, these efforts are often extremely costly and time-consuming, with no guarantee of success. R&D tax credits offer a critical financial incentive that helps pharmaceutical companies offset some of these high costs, allowing them to reinvest in further innovation. By reducing the effective cost of research activities, these credits enable companies to pursue more ambitious and risk-intensive projects that might otherwise be financially unfeasible. For the pharmaceutical industry, R&D tax credits can significantly accelerate the pace of innovation. They encourage continued investment in new drug development, support the creation of cutting-edge treatments, and foster collaboration with academic institutions, research centers, and biotechnology startups. Additionally, these credits can enhance a company’s global competitiveness by improving cash flow and reducing tax liabilities, which is particularly valuable in a sector where long development timelines and regulatory hurdles can delay returns on investment. In a rapidly evolving healthcare landscape, where demand for effective and personalized medicine is growing, the R&D tax credit plays a vital role in sustaining pharmaceutical advancement. It not only supports the discovery of life-saving treatments but also contributes to job creation, economic growth, and improved public health. Overall, the R&D tax credit is a powerful tool that fuels innovation and strengthens the pharmaceutical industry’s ability to deliver better healthcare solutions to society.